A display apparatus according to an embodiment includes light-emitting devices and an encapsulation member, wherein the encapsulation member includes a light absorber including a hexagonal heterocycle containing two or more nitrogen atoms as ring-forming atoms, and first to third substituents substituted at the hexagonal heterocycle, the first to third substituents being different from one another, and thus can effectively block external light, thereby exhibiting improved reliability.

A display apparatus according to an embodiment includes light-emitting devices and an encapsulation member, wherein the encapsulation member includes a light absorber including a hexagonal heterocycle containing two or more nitrogen atoms as ring-forming atoms, and first to third substituents substituted at the hexagonal heterocycle, the first to third substituents being different from one another, and thus can effectively block external light, thereby exhibiting improved reliability.

The present application relates to compounds of formulae (I)-(VII) as defined herein, compositions containing these compounds, methods of their use, and methods of making. The compounds have nematacide activity.

The present application relates to compounds of formulae (I)-(VII) as defined herein, compositions containing these compounds, methods of their use, and methods of making. The compounds have nematacide activity.

The present invention relates to fluorene derivatives and to electronic devices in which these compounds are used as matrix material in the emitting layer and/or as hole-transport material and/or as electron-blocking or exciton-blocking material and/or as electron-transport material.

The present invention relates to fluorene derivatives and to electronic devices in which these compounds are used as matrix material in the emitting layer and/or as hole-transport material and/or as electron-blocking or exciton-blocking material and/or as electron-transport material.

The present invention relates to 2-amino-4-arylpyrimidine and 2-amino-4-aryltriazine compounds as inhibitors of heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of a disorder hi a subject. For example, the disorder is a neurodegenerative disease.

The present invention relates to 2-amino-4-arylpyrimidine and 2-amino-4-aryltriazine compounds as inhibitors of heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of a disorder hi a subject. For example, the disorder is a neurodegenerative disease.

The present invention relates to 5,6-diphenyl-5,6-dihydrodibenz[c,e][1,2]azaphosphorin and 6-phenyl-6H-dibenzo[c,e][1,2]thiazine 5,5-dioxide derivatives and similar compounds of the formula (1) as organic electroluminescent materials for use in organic electroluminescent devices, for example in organic light-emitting diodes (OLEDs), where the symbols used are as follows: Z is the same or different at each instance and is PAr.sup.2 or S(═O); E is the same or different at each instance and is O or S when the symbol Z to which this E binds is PAr.sup.2, and O when the symbol Z to which this E binds is S(═O); L is selected from the group consisting of a single bond, NAr.sup.2, O, S, S(═O).sub.2, P(═O)Ar.sup.2, —X═X— and —C(═O)—NAr.sup.2; the rest of the symbols are defined in the claims. The present invention discloses synthesis examples of inventive compounds, productions of OLEDs containing these example compounds, and results for these electroluminescent devices.

The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.